

Trabajo Original



Is Non-alcoholic Fatty Pancreas a Mechanism of Beta-cells Dedifferentiation to Trigger Type 2 Diabetes Mellitus?

DE OLIVEIRA ANDRADE LJ¹, CORREIA MATOS DE OLIVEIRA G², VINHAES BITTENCOURT AM³,
MATOS DE OLIVEIRA L⁴, MAGNO BAPTISTA G¹

¹Departamento de Saúde – Universidade Estadual de Santa Cruz – Ilhéus – Bahia – Brazil.

²Facultad de Medicina – UniFTC – Salvador – Bahia – Brazil.

³Facultad de Medicina – Universidade Federal da Bahia – Salvador – Bahia - Brazil.

⁴Facultad de Medicina – Bahia – Brazil.

INFORMACIÓN DEL ARTÍCULO

Historia del artículo:

Recibido: 22 de junio de 2021

Revisión: 4 de agosto de 2021

Aceptado: 25 de septiembre de 2021

Palabras clave:

Páncreas graso no alcohólico

Resistencia a la insulina

Células beta

Desdiferenciación celular

Vía de señalización

Diabetes mellitus tipo 2

RESUMEN

La esteatosis pancreática es una enfermedad en la que se produce una acumulación de grasa en las células acinares pancreáticas o en los islotes pancreáticos. Se presume que la enfermedad grasa pancreática no alcohólica (EGPNA) induce la dediferenciación de las células beta, afectando a la secreción de insulina y al metabolismo de la glucosa. El objetivo fue evaluar la interacción entre el EGPNA y la resistencia a la insulina (RI) como mecanismo de dediferenciación de las células beta en el desencadenamiento de la diabetes mellitus tipo 2 (DM2) mediante la elaboración de una vía de señalización. Se realizó un estudio descriptivo con el desarrollo de un diseño de vía de señalización. Se utilizó la base de datos de la Enciclopedia de Genes y Genomas de Kioto para analizar la interacción proteína-proteína y realizar el mapeo de las vías de señalización. El proyecto de diseño de la vía de señalización se realizó con el software PathVisio. Basándonos en artículos de investigación, seleccionamos las vías bien documentadas y obtuvimos perfiles de expresión específicos de estas vías. Los "contigs" de transcripción extraídos de la Enciclopedia de Genes y Genomas de Kioto delinearón la vía de señalización de las biomoléculas clave que desencadenaron la pérdida de la función de las células beta. La interacción entre EGPNA y el RI libera factores inflamatorios que contribuyen al posible mecanismo de desarrollo de la dediferenciación de las células beta.

En conclusión, la interacción entre el EGPNA y el RI demuestra ser dos índices importantes para el posible mecanismo de dediferenciación de las células beta en el desencadenamiento de la DM2, como se demuestra a través de la vía de señalización.

ABSTRACT

Keywords:

Non-alcoholic fatty pancreas
 Insulin resistance
 Beta-cells
 Cell Dedifferentiation
 Signaling pathway
 Type 2 diabetes mellitus

Pancreatic steatosis is a condition where there is a fat accumulation in acinar cells of the pancreas or in the pancreatic islets. It is presumed that non-alcoholic fatty pancreatic disease (NAFPD) induce beta-cell dedifferentiation, affecting the insulin secretion and glucose metabolism. The objective was to evaluate the interaction between NAFPD and insulin resistance (IR) as a mechanism of beta-cell dedifferentiation in development of type 2 diabetes mellitus (DM2) through the signaling pathway design. Descriptive study with the elaboration of signaling pathway design was done. The Kyoto Encyclopedia of Genes and Genomes server was used to analyze protein-protein interaction and perform signaling pathway mapping. The signaling pathway diagram design was done with PathVisio software. Based on research articles, we selected well-documented pathways and obtained specific expression profiles of these pathways. The transcription contigs extracted from the Kyoto Encyclopedia of Genes and Genomes database delineated the signaling pathway of the key biomolecules that triggered to the loss of function of the beta-cell. The interaction between NAFPD and IR release inflammatory factors that contribute to the possible development mechanism of beta-cell dedifferentiation.

In conclusion, the interaction between NAFPD and IR prove to be two important indices to the possible mechanism of beta-cell dedifferentiation in development of DM2 as demonstrated through of signaling pathway.

INTRODUCTION

The non-alcoholic fatty pancreatic disease (NAFPD) consists in the excessive fatty accumulation of the pancreas, and the pancreatic steatosis is defined as fatty infiltration in the pancreatic islets or acinar cells⁽¹⁾, as consequence of ectopic fat deposition in a non-fatty tissue. Studies estimate the prevalence of NAFPD to be 10% in the pediatric population and to range from 16 to 35% in that in the adult population⁽²⁾. A high frequency between NAFPD and type 2 diabetes mellitus (DM2) has been observed⁽³⁾. Emphasis has been placed on the influence of pancreatic steatosis as a cause of beta-cell dedifferentiation due to increased fatty acids in the pancreatic islets, this being the likely key mechanism for the onset of DM2⁽⁴⁾.

The beta-cell dedifferentiation is defined as a phenotypic alteration of the beta-cell that leads to the loss of its insulin-secreting function and consequent triggering of diabetes mellitus through negative gene regulation of beta-cell, or the simultaneous positive regulation of genes expressed or suppressed in normal beta-cell, or the possible positive regulation of genes from progenitor cells⁽⁵⁾. However, it can also correspond to damage of differentiated cellular elements, leading to heterogeneity of immature primitive beta-cell⁽⁶⁾. Thus, the beta-cell dedifferentiation ultimately leads to a major dysfunction in insulin secretion.

Beta-cell dedifferentiation as a mechanism of beta-cell failure and development of DM2 was a concept introduced Talchai et

al⁽⁷⁾. Probably, the indirect effects associated with insulin resistance (IR) have an important impact on beta-cell dedifferentiation⁽⁸⁾. The beta-cell mechanisms that protect against dedifferentiation have not yet been determined.

Studies show that NAFPD is associated with IR⁽⁹⁾. The IR increases during the course of DM2 progression; however, beta-cell function deteriorates rapidly, and this functional depletion will distinguish individuals who will develop beta-cell dedifferentiation evolving to diabetes or not⁽¹⁰⁾.

The purpose of this study was to evaluate the interaction between NAFPD and IR as a mechanism of beta-cell dedifferentiation in development of DM2 through the signaling pathway design, based in research articles.

MATERIALS AND METHODS

Modeling

The design of molecular pathway maps implies careful extraction of molecular characteristics from the literature and other means accompanied by setting of the multiple elements into a network of interconnected and interacting events.

Based in research articles, we selected well-documented pathways and obtained specific expression profiles of these pathways. PubMed and Google Scholar were utilized to search for proofread publications that have investigated the NAFPD,

IR, and beta-cell dedifferentiation. The signaling pathway reference data was selected by incorporating information from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The KEGG is a database with a collection of biological information about signaling pathway maps, genome sequencing, biological process networks, protein domains, with the goal of utilizing and understanding these functions at a high level⁽¹⁾.

We investigated a total of 30 signaling pathways in the KEGG databases, and for each pathway we identify all the proteins related to pancreas, beta-cell, IR, and DM2 commons between beta-cell dedifferentiation and NAFLD. We subsequently compared the proteins and the six-way interactions. The KEGG database includes various types of information about proteins, containing pathway reports demonstrated in graphical models that make it possible to conceive of protein interactions in complex biological methods.

The MODELLER 10.1 package was used to predict 3-dimensional structure based on the homology modeling protocol. MODELLER is software for comparative modeling of protein structure by alignment of a sequence that will be modeled with the model structures. Based on the resulting structure, we have designed the peptide activators of signaling pathway.

The signaling pathway diagram design was done with PathVisio software (version 3.2.4), and was utilized for the graphic demonstration of signaling pathway since it is a tool that allows view and edit of biological signaling pathways. PathVisio is a public domain pathway editor, analysis and visualization software that is incorporated into the community pathway database WikiPathways one popular free of charge accessible databases for biological pathways evaluation. However, our study was conducted using the KEGG database.


RESULTS and DISCUSSION

Non-alcoholic fatty pancreatic disease, insulin resistance, and beta-cell dedifferentiation - Signaling pathway diagram design

In our work, we coupled a review study with computational modeling to understand the signaling mechanisms that lead NAFLD to trigger IR and beta-cell dedifferentiation having DM2 as an outcome.

The several basic mechanisms of NAFLD as well as their interaction with beta-cell dedifferentiation in triggering of DM2 are demonstrated in Figure 1.

Figure 1. Non-alcoholic fatty pancreatic disease, insulin resistance, and beta-cell dedifferentiation - Signaling pathway diagram design



NAFPD describes a spectrum ranging from simple pancreatic steatosis to severe steatopancreatitis with pancreatic inflammation and fibrosis, referred to as non-alcoholic steatopancreatitis (NASP).

In the early phase of NAFPD an accumulation of adipose tissue occurs activating inflammatory factors. The activation of interleukins is primarily caused by the IR, leading to altered insulin release and elimination of free fatty acids (FFA)⁽¹²⁾. In addition, the activation of a key-enzyme of the lipogenesis by factor Peroxisome Proliferator-Activated Receptor- α (PPAR- α) leads to increased FFA synthesis by the pancreas⁽¹³⁾. As NASP progresses into a subsequent phase, as a result of increased endoplasmic reticulum stress and oxidative stress via mitochondrial beta-oxidation, an increase in reactive oxygen species occurs with consequent lipid peroxidation. This lipid peroxidation increases the production of cytokines and caspases leading to apoptosis, inflammation, and fibrosis⁽¹⁴⁾. Chronic inflammation is one of the causes leading to IR, and the inflammatory state subsequent to visceral fat increment is one of the determinants of pro-inflammatory cytokine production, comprising interleukin 6 (IL-6), tumor necrosis factor alpha (TNF- α), and the profibrogenic adipokine leptin. Furthermore, progression to IR following deactivation of the regulatory signaling pathway \rightarrow serine/threonine kinase (STK) phosphoinositide-3-kinase (PIK3), leads to the development of IR of pancreatic cells resulting in NAFPD.

Several mechanisms are involved in the genesis of IR, comprising incrementation of insulin receptor substrate (IRS) protein phosphorylation by the inhibitor of nuclear factor kappa B kinase subunit beta, c-Jun N-terminal protein kinase 1, and protein kinase C⁽¹⁵⁾. The IR has with consequence also deterioration of the IRS-1 proteasome through mammalian target of rapamycin (mTOR), elevating the effects of phosphatase and tensin homolog (PTEN), of protein phosphatase 2A (PPA2) and of protein tyrosine phosphatase (PTPs); furthermore, it reduces the activation of the signaling molecules such as protein kinase B (AKT) and PI3K⁽¹⁶⁾. Cell differentiation involves synchronous and tightly controlled activation/repression of specific genes and effectors in a time-dependent manner, giving rise to cells with specific morpho-functional properties. Dedifferentiation, on the other hand, involves the loss to varying degrees of cellular identity and phenotype and may regress to a less differentiated or precursor-like condition⁽⁵⁾.

Recent data support that beta-cell dedifferentiation alters insulin secretion, and plays an important role in triggering DM2^(7,17). Thus, the beta-cell dedifferentiated has a tendency to transform into other non-beta cell endocrine cells that cause the development of diabetes⁽¹⁸⁾.

The disturbance in glucose metabolism involves high demand for insulin secretion with increased levels of reactive oxygen species (ROS) in the beta-cell that consequently release chemokines that recruit macrophages leading to increased beta-cell dedifferentiation by inflammatory processes with reduced beta-cell mass⁽⁸⁾. The beta-cell are especially sensitive to

oxidative stress because of their elevated ROS production with reduced antioxidant potency, indicating that oxidative stress may play a significant role in pancreatic beta cell failure resulting in DM2⁽¹⁹⁾.

Glucose transporter 2 (GLUT2) is main glucose transporter in beta-cells of pancreatic islets, mediating the diffusion of glucose through of cell membrane, and plays a crucial role in glucose metabolism⁽²⁰⁾.

Neurogenin 3 is a pancreatic endocrine lineage-specific marker being an important regulator in beta-cell regeneration and differentiation, as well as stimulating the expression glucose sensor glucokinase of beta-cell. However, the neurogenin 3 does not stimulate the glucose transporter GLUT-2^(21,22).

The octamer-binding transcription factor 4 (Oct-4) is a protein that is implicated in maintaining the self-renewal of undifferentiated, pluripotent embryonic stem-cells. There are three isoforms of Oct-4, of which Oct-4b is essential in the response to stress, whereas the other isoforms are related to plasticity and to the activation or inactivation of beta-cell dedifferentiation⁽²³⁾.

Mitochondrial beta-oxidation involves linear chain fatty acids structured into two functional subdomains by via a complex pathway under intramitochondrial command. Increased fatty acid beta-oxidation reduces lipid accumulation in the cytoplasm by decreasing glucose metabolism, and incomplete oxidation potentially contributes to IR⁽²⁴⁾. In vitro studies demonstrate that high levels of fatty acids induce glycototoxicity and beta-cell dysfunction; thus, lipid accumulation in the pancreas demonstrated the presence of IR and DM2⁽²⁵⁾.

Forkhead box protein O1 (FoxO1) is essential for insulin action. FoxO1 is a conserved transcription factor that has direct interaction with genes involved in gluconeogenesis and metabolic regulation⁽²⁶⁾. FoxO1 regulates glucose homeostasis in beta-cells and peripheral tissues, and its activation leads to IR and beta-cell dedifferentiation, while decreasing its function can restore pancreatic beta-cell function by reversing hyperglycemia⁽²⁷⁾.

Oxidative phosphorylation in mitochondria is made up of five complexes that are fundamental in regulating cellular metabolism, and precisely the ATP-producing oxidative phosphorylation pathway is essential in insulin secretion.⁽²⁸⁾ Recent studies put altered oxidative phosphorylation as a key genetic component of IR⁽²⁹⁾.

Nanog is as one of the heterogeneously express genes in induced pluripotent stem-cell and embryonic-stem populations. It performs an essential role in self-renewal cellular, maintenance, and pluripotency. In addition, Nanog has directed each other interactions with Oct4 and Sox2 genes⁽³⁰⁾. The pluripotent bone marrow stromal cells that co-expressing NANOG can be differentiated in beta-cells⁽³¹⁾. Beta-cell dedifferentiation happens often in DM2 and is link to with an arising loss of FoxO1 function, and there exists an opposite link between beta-cell differentiation and FoxO1 as DM2 progresses, with a significant elevation of Nanog expression⁽⁷⁾.

CONCLUSIONS

Beta-cell dedifferentiation happens often in DM2, and the interaction between NAFLD and IR prove to be two important indices to the possible mechanism of beta-cell dedifferentiation in development of DM2 as demonstrated through in signaling pathway.

CONFLICT OF INTEREST:

The authors declare that there is no conflict of interests regarding the publication of this paper.

BIBLIOGRAPHY

1. **Pezzilli R, Calculli L.** Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? *World J Diabetes.* 2014; 5:415-19.
 2. **Rico-De La Rosa L, Cervantes-Pérez E, Robledo-Valdez M, Padilla-Rubio MF, Villaseñor-Ochoa A, Ramírez-Casa E Fi, et al.** Enfermedad pancreática grasa no alcohólica: implicaciones actuales en la práctica clínica. *Rev Argent Endocrinol y Metab.* 2021; 58:27-35.
 3. **Jeong JS, Kim MK, Han KD, Hong OK, Baek KH, Song KH, et al.** The Association between Pancreatic Steatosis and Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients. *Diabetes Metab J.* 2018; 42:425-32.
 4. **Tirkes T, Jeon CY, Li L, Joon AY, Seltman TA, Sankar M, et al.** Association of Pancreatic Steatosis With Chronic Pancreatitis, Obesity, and Type 2 Diabetes Mellitus. *Pancreas.* 2019; 48:420-6.
 5. **Bensellam M, Jonas JC, Laybutt DR.** Mechanisms of beta-cell dedifferentiation in diabetes: recent findings and future research directions. *J Endocrinol.* 2018; 236:R109-R143.
 6. **Weir GC, Aguayo-Mazzucato C, Bonner-Weir S.** Beta-cell dedifferentiation in diabetes is important, but what is it? *Islets.* 2013; 5:233-7.
 7. **Talchai C, Xuan S, Lin HV, Sussel L, Accili D.** Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. *Cell.* 2012; 150:1223-4.
 8. **Nordmann TM, Dror E, Schulze F, Traub S, Berishvili E, Barbieux C, et al.** The Role of Inflammation in β -cell Dedifferentiation. *Sci Rep.* 2017; 7:6285.
 9. **Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, et al.** Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. *Gastroenterol Res Pract.* 2013; 2013:498296.
 10. **Weyer C, Bogardus C, Mott DM, Pratley RE.** The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest.* 1999; 104:787-94.
 11. **Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K.** KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 2017; 45:D353-61.
 12. **Li J, Zhang Y, Ye Y, Li D, Liu Y, Lee E, et al.** Pancreatic beta cells control glucose homeostasis via the secretion of exosomal miR-29 family. *Extracell Vesicles.* 2021; 10:e12055.
 13. **Lesmana CR, Pakasi LS, Inggriani S, Aidawati ML, Lesmana LA.** Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFLD) and its risk factors among adult medical check-up patients in a private hospital: a large cross-sectional study. *BMC Gastroenterol.* 2015; 15:174.
 14. **Smits MM, van Geenen EJ.** The clinical significance of pancreatic steatosis. *Nat Rev Gastroenterol Hepatol.* 2011; 8:169-177.
 15. **Boura-Halfon S, Zick Y.** Phosphorylation of IRS proteins, insulin action, and insulin resistance. *Am J Physiol Endocrinol Metab.* 2009; 296:E581-91.
 16. **Pirola L, Bonnafous S, Johnston AM, Chaussade C, Portis F, Van Obberghen E.** Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. *J Biol Chem.* 2003; 278:15641-51.
 17. **Cinti F, Bouchi R, Kim-Muller JY, Ohmura Y, Sandoval PR, Masini M, et al.** Evidence of beta-Cell Dedifferentiation in Human Type 2 Diabetes. *J Clin Endocrinol Metab.* 2016; 101:1044-54.
 18. **Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, et al.** Fasting-Mimicking Diet Promotes Ngn3-Driven β -Cell Regeneration to Reverse Diabetes. *Cell.* 2017; 168:775-788.e12.
 19. **Eguchi N, Vaziri ND, Dafeo DC, Ichii H.** The Role of Oxidative Stress in Pancreatic beta Cell Dysfunction in Diabetes. *Int J Mol Sci.* 2021; 22:1509.
 20. **Wu L, Fritz JD, Powers AC.** Different functional domains of GLUT2 glucose transporter are required for glucose affinity and substrate specificity. *Endocrinology.* 1998; 139:4205-12.
 21. **Rukstalis JM, Habener JF.** Neurogenin3: a master regulator of pancreatic islet differentiation and regeneration. *Islets.* 2009; 1:177-84.
 22. **Gasa R, Mrejen C, Leachman N, Otten M, Barnes M, Wang J, et al.** Proendocrine genes coordinate the pancreatic islet differentiation program in vitro. *Proc Natl Acad Sci USA.* 2004; 101:13245-50.
 23. **Kalsotra A, Cooper TA.** Functional consequences of developmentally regulated alternative splicing. *Nat Rev Genet.* 2011; 12:715-29.
 24. **Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD.** Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. *Biochim Biophys Acta.* 2010; 1801:1-22.
 25. **van Raalte DH, van der Zijl NJ, Diamant M.** Pancreatic steatosis in humans: cause or marker of lipotoxicity? *Curr Opin Clin Nutr Metab Care.* 2010; 13:478-85.
 26. **Peng S, Li W, Hou N, Huang N.** A Review of FoxO1-Regulated Metabolic Diseases and Related Drug Discoveries.
-

-
- Cells. 2020; 9:184.
27. **Luong N, Davies CR, Wessells RJ, Graham SM, King MT, Veech R, et al.** Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. *Cell Metab.* 2006; 4:133-42.
 28. **Lang AL, Caicedo A.** Effects of Oxidative Phosphorylation Complex Defects on Beta-Cell Biology. *Diabetes* 2020; 69(Supplement 1):doi.org/10.2337/db20-249-LB
 29. **Newsholme P, Gaudel C, Krause M.** Mitochondria and diabetes. An intriguing pathogenetic role. *Adv Exp Med Biol.* 2012; 942:235-47.
 30. **Yu P, Nie Q, Tang C, Zhang L.** Nanog induced intermediate state in regulating stem cell differentiation and reprogramming. *BMC Syst Biol.* 2018; 12:22.
 31. **Zhao M, Amiel SA, Ajami S, Jiang J, Rela M, Heaton N, Huang CC.** Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. *PLoS One.* 2008; 3:e2666.
-

